Splicing variants of androgen receptor in prostate cancer

American Journal of Clinical and Experimental Urology

Yang Zhan¹  Yanfeng Qi¹  Yan Dong¹  Guanyi Zhang¹  Xichun Liu¹  Oliver Sartor¹  Haitao Zhang¹ 

关键词: Androgen receptor;    AR splice variants;    castration resistance;    prostate cancer;   

DOI  :  

学科分类：医学（综合）

来源: e-Century Publishing Corporation

【 摘 要 】

Significant advances in our understanding of continued androgen receptor (AR) signaling in castration-resistant prostate cancer have led to the development and FDA approval of two next-generation androgen-directed therapies, abiraterone and enzalutamide. These new therapies heralded a new era of prostate cancer therapy. However, disease progression during androgen-directed therapies remains the most critical challenge in the clinical management of prostate cancer. Accumulating evidence points to an important contribution of constitutively-active AR splice variants to AR-driven tumor progression during androgen-directed therapies. In this review, we will focus on the structure, activity, detection, clinical relevance, and mechanisms of production of AR splice variants.

【 授权许可】

Unknown